TGFB1 and Hepatic fibrosis: In vivo studies disclose an anti-fibrotic effect of MSC like against skeletal muscular fibrosis, primarily through MMP-1 [124], or kidney or liver fibrosis via VEGF and HGF secretion, and further eliminates TGF-β1-induced fibrotic changes [125,126], with TGF-β1/Smad route which is a major pathogenic mechanism in tissue fibrosis [127,128].